Glycosidated phospholipids - a promising group of anti-tumour lipids

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 4, 2014, Pages 607-617

  Semini, Geo ^a   Hildmann, Annette ^a   von Haefen, Clarissa ^a   Danker, Kerstin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Cell proliferation; Differentiation; Gene expression; Glycosidated phospholipids; Migration

Indexed keywords

BETA1 INTEGRIN; CASPASE 3; CASPASE 8; CHAPERONIN CONTAINING TCP1; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; COLLAGEN TYPE 4; EDELFOSINE; FAS ANTIGEN; FIBRONECTIN; GLUCOSE PLATELET ACTIVATING FACTOR; GLYCOSIDATED PHOSPHOLIPID; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; INOSITOL C2 PLATELET ACTIVATING FACTOR; INVOLUCRIN; LAMININ; LAMININ 111; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERIFOSINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; RAF PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CYTOTOXICITY; DNA FRAGMENTATION; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; KERATINOCYTE; MICROARRAY ANALYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROSIS; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLYCOSYLATION; HUMANS; INOSITOL; NEOPLASMS; PHOSPHOLIPIDS; PLATELET ACTIVATING FACTOR;

EID: 84908118950     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140309222845     Document Type: Article

References (116)

1. Danker, K.; Reutter, W.; Semini, G. Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Brit. J. Pharmacol., 2010, 160(1), 36-47.
2. Andreesen, R.; Modolell, M.; Munder, P.G. Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood, 1979, 54(2), 519-523.
3. Andreesen, R.; Modolell, M.; Weltzien, H.U.; Eibl, H.; Common, H.H.; Lohr, G.W.; Munder, P.G. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res., 1978, 38(11 Pt 1), 3894-3899.
4. Modolell, M.; Andreesen, R.; Pahlke, W.; Brugger, U.; Munder, P.G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res., 1979, 39(11), 4681-4686.
5. Munder, P.G. Antitumor activity of alkyllysophospholipids. Human Cancer Immunol., 1982, 3, 17-29.
6. Munder, P.G.; Modolell, M.; Andreesen, R.; Weltzien, H.U.; Westphal, O. Lysophosphatidylcholine(Lysolecithin) and its synthetic analogues. Immune modulating and other biologic effects. Immuno-pathology, 1979, 2, 187-203.
7. Tarnowski, G.S.; Mountain, I.M.; Stock, C.C.; Munder, P.G.; Weltzien, H.U.; Westphal, O. Effect of lysolecithin and analogs on mouse ascites tumors. Cancer Res., 1978, 38(2), 339-344.
8. Chignard, M.; Le Couedic, J.P.; Tence, M.; Vargaftig, B.B.; Benveniste, J. The role of platelet-activating factor in platelet aggregation. Nature, 1979, 279(5716), 799-800.
9. Edwards, L.J.; Constantinescu, C.S. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Infl. Allergy Drug Targets, 2009, 8(3), 182-190.
10. Prescott, S.M.; Zimmerman, G.A.; McIntyre, T.M. Platelet-activating factor. J. Biol. Chem., 1990, 265(29), 17381-17384.
11. Snyder, F. Platelet-activating factor: The biosynthetic and catabolic enzymes. Biochem. J., 1995, 305(Pt 3), 689-705.
12. Wolf, P.; Nghiem, D.X.; Walterscheid, J.P.; Byrne, S.; Matsumura, Y.; Matsumura, Y.; Bucana, C.; Ananthaswamy, H.N.; Ullrich, S.E. Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am. J. Pathol., 2006, 169(3), 795-805.
13. Gajate, C.; Mollinedo, F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3)(edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metabol., 2002, 3(5), 491-525.
14. van Blitterswijk, W.J.; Verheij, M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharmaceut. Design, 2008, 14(21), 2061-2074.
15. Unger, C.; Fleer, E.A.; Kotting, J.; Neumuller, W.; Eibl, H. Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines. Prog. Exp. Tumor Res., 1992, 34, 25-32.
16. Noseda, A.; White, J.G.; Godwin, P.L.; Jerome, W.G.; Modest, E.J. Membrane damage in leukemic cells induced by ether and ester lipids: an electron microscopic study. Exp. Mol. Pathol., 1989, 50(1), 69-83.
17. Tertoolen, L.G.; Kempenaar, J.; Boonstra, J.; de Laat, S.W.; Ponec, M. Lateral mobility of plasma membrane lipids in normal and transformed keratinocytes. Biochem. Biophys. Res. Commun., 1988, 152(2), 491-496.
18. Kelley, E.E.; Modest, E.J.; Burns, C.P. Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem. Pharmacol., 1993, 45(12), 2435-2439.
19. Van Blitterswijk, W.J.; Van der Bend, R.L.; Kramer, I.M.; Verhoeven, A.J.; Hilkmann, H.; De Widt, J. A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signalling via protein kinase C. Lipids, 1987, 22(11), 842-846.
20. Wiese, A.; Wieder, T.; Mickeleit, M.; Reinohl, S.; Geilen, C.C.; Seydel, U.; Reutter, W. Structure-dependent effects of glucose-containing analogs of platelet activating factor(PAF) on membrane integrity. Biol. Chem., 2000, 381(2), 135-144.
21. Van der Veer, E.; Van der Weide, D.; Heijmans, H.S.; Hoekstra, D. Translocation of fluorescent ether phospholipid, but not its diacyl counterpart, after insertion in plasma membranes of control and plasmalogen-deficient fibroblasts. Biochim. Biophys. Acta, 1993, 1146(2), 294-300.
22. Bratton, D.L.; Dreyer, E.; Kailey, J.M.; Fadok, V.A.; Clay, K.L.; Henson, P.M. The mechanism of internalization of platelet-activating factor in activated human neutrophils. Enhanced transbilayer movement across the plasma membrane. J. Immunol., 1992, 148(2), 514-523.
23. Fleer, E.A.; Berkovic, D.; Unger, C.; Eibl, H. Cellular uptake and metabolic fate of hexadecylphosphocholine. Prog. Exp. Tumor Res., 1992, 34, 33-46.
24. Wirtz, K.W. Phospholipid transfer proteins. Ann. Rev. Biochem., 1991, 60, 73-99.
25. Ausili, A.; Torrecillas, A.; Aranda, F.J.; Mollinedo, F.; Gajate, C.; Corbalan-Garcia, S.; De Godos, A.; Gomez-Fernandez, J.C. Edelfosine is incorporated into rafts and alters their organization. J. Phys. Chem., 2008, 112(37), 11643-11654.
26. Heczkova, B.; Slotte, J.P. Effect of anti-tumor ether lipids on ordered domains in model membranes. FEBS Lett., 2006, 580(10), 2471-2476.
27. Van der Luit, A.H.; Budde, M.; Zerp, S.; Caan, W.; Klarenbeek, J.B.; Verheij, M.; Van Blitterswijk, W.J. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem. J., 2007, 401(2), 541-549.
28. Foller, M.; Huber, S.M.; Lang, F. Erythrocyte programmed cell death. IUBMB Life, 2008, 60(10), 661-668.
29. Lang, P.A.; Kempe, D.S.; Tanneur, V.; Eisele, K.; Klarl, B.A.; Myssina, S.; Jendrossek, V.; Ishii, S.; Shimizu, T.; Waidmann, M.; Hessler, G.; Huber, S.M.; Lang, F.; Wieder, T. Stimulation of erythrocyte ceramide formation by platelet-activating factor. J. Cell Sci., 2005, 118(Pt 6), 1233-1243.
30. Rahmani, M.; Reese, E.; Dai, Y.; Bauer, C.; Payne, S.G.; Dent, P.; Spiegel, S.; Grant, S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res., 2005, 65(6), 2422-2432.
31. Wieder, T.; Orfanos, C.E.; Geilen, C.C. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J. Biol. Chem., 1998, 273(18), 11025-11031.
32. Daniel, L.W.; Waite, M.; Wykle, R.L. A novel mechanism of diglyceride formation. 12-O-tetradecanoylphorbol-13-acetate stimulates the cyclic breakdown and resynthesis of phosphatidylcholine. J. Biol. Chem., 1986, 261(20), 9128-9132.
33. Exton, J.H. Effects of extracellular ATP on phosphatidylcholine phospholipase signaling systems. Ann. New York Acad. Sci., 1990, 603, 246-254; discussion 254-245.
34. Haase, R.; Wieder, T.; Geilen, C.C.; Reutter, W. The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. FEBS Lett., 1991, 288(1-2), 129-132.
35. Geilen, C.C.; Wieder, T.; Reutter, W. Hexadecylphosphocholine inhibits translocation of CTP: Choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. J. Biol. Chem., 1992, 267(10), 6719-6724.
36. Jimenez-Lopez, J.M.; Carrasco, M.P.; Segovia, J.L.; Marco, C. Hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis and the proliferation of HepG2 cells. Eu. J. Biochem./ FEBS, 2002, 269(18), 4649-4655.
37. Attard, G.S.; Templer, R.H.; Smith, W.S.; Hunt, A.N.; Jackowski, S. Modulation of CTP: Phosphocholine cytidylyltransferase by membrane curvature elastic stress. Proc. Natl. Acad. Sci. USA, 2000, 97(16), 9032-9036.
38. Baburina, I.; Jackowski, S. Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP: Phosphocholine cytidylyltransferase. J. Biol. Chem., 1998, 273(4), 2169-2173.
39. Boggs, K.; Rock, C.O.; Jackowski, S. The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. Biochim. Biophys. Acta, 1998, 1389(1), 1-12.
40. Boggs, K.P.; Rock, C.O.; Jackowski, S. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine. J. Biol. Chem., 1995, 270(19), 11612-11618.
41. Boggs, K.P.; Rock, C.O.; Jackowski, S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP: phosphocholine cytidylyltransferase step. J. Biol. Chem., 1995, 270(13), 7757-7764.
42. van der Luit, A.H.; Budde, M.; Ruurs, P.; Verheij, M.; Van Blitterswijk, W.J. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J. Biol. Chem., 2002, 277(42), 39541-39547.
43. Dymond, M.; Attard, G.; Postle, A.D. Testing the hypothesis that amphiphilic antineoplastic lipid analogues act through reduction of membrane curvature elastic stress. J. Royal Soc., 2008, 5(28), 1371-1386.
44. Daniel, L.W.; Etkin, L.A.; Morrison, B.T.; Parker, J.; Morris-Natschke, S.; Surles, J.R.; Piantadosi, C. Ether lipids inhibit the effects of phorbol diester tumor promoters. Lipids, 1987, 22(11), 851-855.
45. Geilen, C.C.; Haase, R.; Buchner, K.; Wieder, T.; Hucho, F.; Reutter, W. The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur. J. Cancer, 1991, 27(12), 1650-1653.
46. Berkovic, D.; Berkovic, K.; Fleer, E.A.; Eibl, H.; Unger, C. Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines. Eur. J. Cancer, 1994, 30A(4), 509-515.
47. Diomede, L.; Piovani, B.; Re, F.; Principe, P.; Colotta, F.; Modest, E.J.; Salmona, M. The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. Int. J. Cancer, 1994, 57(5), 645-649.
48. Houlihan, W.J.; Lohmeyer, M.; Workman, P.; Cheon, S.H. Phospholipid antitumor agents. Med. Res. Rev., 1995, 15(3), 157-223.
49. Mollinedo, F.; Martinez-Dalmau, R.; Modolell, M. Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem. Biophys. Res. Commun., 1993, 192(2), 603-609.
50. Munder, P.G.; Westphal, O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol., 1990, 49, 206-235.
51. Mollinedo, F.; Fernandez-Luna, J.L.; Gajate, C.; Martin-Martin, B.; Benito, A.; Martinez-Dalmau, R.; Modolell, M. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3(Edelfosine): Molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res., 1997, 57(7), 1320-1328.
52. Cabaner, C.; Gajate, C.; Macho, A.; Munoz, E.; Modolell, M.; Mollinedo, F. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: Involvement of the Fas receptor/ligand system. Br. J. Pharmacol., 1999, 127(4), 813-825.
53. Gajate, C.; Santos-Beneit, A.M.; Macho, A.; Lazaro, M.; Hernandez-De Rojas, A.; Modolell, M.; Munoz, E.; Mollinedo, F. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int. J. Cancer, 2000, 86(2), 208-218.
54. Elrod, H.A.; Lin, Y.D.; Yue, P.; Wang, X.; Lonial, S.; Khuri, F.R.; Sun, S.Y. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol. Cancer Therapeutics, 2007, 6(7), 2029-2038.
55. Engel, J.B.; Honig, A.; Schonhals, T.; Weidler, C.; Hausler, S.; Krockenberger, M.; Grunewald, T.G.; Dombrowski, Y.; Rieger, L.; Dietl, J.; Wischhusen, J. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. Eu. J. Obstetrics Gynecol. Reprod. Biol., 2008, 141(1), 64-69.
56. Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Therapeutics, 2003, 2(11), 1093-1103.
57. Na, H.K.; Surh, Y.J. The antitumor ether lipid edelfosine(ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: by blocking ERK1/2 and p38 mitogen-activated protein kinases as potential targets. Asia Pacific J. Clin. Nutr., 2008, 17 Suppl 1, 204-207.
58. Nyakern, M.; Cappellini, A.; Mantovani, I.; Martelli, A.M. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Therapeutics, 2006, 5(6), 1559-1570.
59. Papa, V.; Tazzari, P.L.; Chiarini, F.; Cappellini, A.; Ricci, F.; Billi, A.M.; Evangelisti, C.; Ottaviani, E.; Martinelli, G.; Testoni, N.; McCubrey, J.A.; Martelli, A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 2008, 22(1), 147-160.
60. Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; Van Blitterswijk, W.J.; Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti-Cancer Drugs, 2003, 14(2), 167-173.
61. Chen, Z.; Gibson, T.B.; Robinson, F.; Silvestro, L.; Pearson, G.; Xu, B.; Wright, A.; Vanderbilt, C.; Cobb, M.H. MAP kinases. Chem. Rev., 2001, 101(8), 2449-2476.
62. Kyriakis, J.M.; Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev., 2001, 81(2), 807-869.
63. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B.E.; Karandikar, M.; Berman, K.; Cobb, M.H. Mitogen-activated protein(MAP) kinase pathways: Regulation and physiological functions. Endocrine Rev., 2001, 22(2), 153-183.
64. Samadder, P.; Arthur, G. Decreased sensitivity to 1-O-octadecyl-2-O-methyl-glycerophosphocholine in MCF-7 cells adapted for serum-free growth correlates with constitutive association of Raf-1 with cellular membranes. Cancer Res., 1999, 59(19), 4808-4815.
65. Samadder, P.; Richards, C.; Bittman, R.; Bhullar, R.P.; Arthur, G. The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine(ET-18-OCH3) inhibits the association between Ras and Raf-1. Anticancer Res., 2003, 23(3B), 2291-2295.
66. Gajate, C.; Santos-Beneit, A.; Modolell, M.; Mollinedo, F. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol. Pharmacol., 1998, 53(4), 602-612.
67. Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N.C.; Chauhan, D.; Richardson, P.G.; Anderson, K.C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107(10), 4053-4062.
68. Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; van Blitterswijk, W.J.; Verheij, M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res., 1999, 59(10), 2457-2463.
69. Mickeleit, M.; Wieder, T.; Arnold, M.; Geilen, C.C.; Mulzer, J.; Reutter, W. A glucose-containing ether lipid(Glc-PAF) as an antiproliferative analogue of the platelet-activating factor. Angew. Chem. Int. Ed., 1998, 37(3), 351-353.
70. Mickeleit, M.; Wieder, T.; Buchner, K.; Geilen, C.C.; Mulzer, J.; Reutter, W. Glc-PC, a new type of glucosidic phospholipid. Angew. Chem. Int. Ed. Engl., 1995, 34(23/24), 2667-2669.
71. Marino-Albernas, J.R.; Bittman, R.; Peters, A.; Mayhew, E. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3(edelfosine). J. Med. Chem., 1996, 39(17), 3241-3247.
72. Samadder, P.; Byun, H.S.; Bittman, R.; Arthur, G. Glycosylated antitumor ether lipids are more effective against oncogene-transformed fibroblasts than alkyllysophospholipids. Anticancer Res., 1998, 18(1A), 465-470.
73. Dummer, R.; Roger, J.; Vogt, T.; Becker, J.; Hefner, H.; Sindermann, H.; Burg, G. Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. Prog. Exp. Tumor Res., 1992, 34, 160-169.
74. Unger, C.; Peukert, M.; Sindermann, H.; Hilgard, P.; Nagel, G.; Eibl, H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat. Rev., 1990, 17(2-3), 243-246.
75. von Haefen, C.; Wendt, J.; Semini, G.; Sifringer, M.; Belka, C.; Radetzki, S.; Reutter, W.; Daniel, P.T.; Danker, K. Synthetic glycosidated phospholipids induce apoptosis through activation of FADD, caspase-8 and the mitochondrial death pathway. Apoptosis, 2011, 16(6), 636-651.
76. Bartolmas, T.; Heyn, T.; Mickeleit, M.; Fischer, A.; Reutter, W.; Danker, K. Glucosamine-glycerophospholipids that activate cell-matrix adhesion and migration. J. Med. Chem., 2005, 48(21), 6750-6755.
77. Fischer, A.; Muller, D.; Zimmermann-Kordmann, M.; Kleuser, B.; Mickeleit, M.; Laabs, S.; Lowe, W.; Cantagrel, F.; Reutter, W.; Danker, K. The ether lipid inositol-C2-PAF is a potent inhibitor of cell proliferation in HaCaT cells. Chembiochem, 2006, 7(3), 441-449.
78. Gajate, C.; Mollinedo, F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood, 2001, 98(13), 3860-3863.
79. Gajate, C.; Mollinedo, F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood, 2007, 109(2), 711-719.
80. Fischer, A. Aufklärung der Wirkung eines neuartigen, modifizierten Phospholipidanalogons: Inositol-C2-PAF. Free University: Berlin, May 2006.
81. Gajate, C.; Fonteriz, R.I.; Cabaner, C.; Alvarez-Noves, G.; Alvarez-Rodriguez, Y.; Modolell, M.; Mollinedo, F. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer, 2000, 85(5), 674-682.
82. Jendrossek, V.; Muller, I.; Eibl, H.; Belka, C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene, 2003, 22(17), 2621-2631.
83. Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun., 2009, 380(4), 780-784.
84. Vicente-Manzanares, M.; Webb, D.J.; Horwitz, A.R. Cell migration at a glance. J. Cell Sci., 2005, 118(Pt 21), 4917-4919.
85. Raja; Sivamani, K.; Garcia, M.S.; Isseroff, R.R. Wound re-epithelialization: Modulating keratinocyte migration in wound healing. Front. Biosci., 2007, 12, 2849-2868.
86. Werner, S.; Krieg, T.; Smola, H. Keratinocyte-fibroblast interactions in wound healing. J. Investigat. Dermatol., 2007, 127(5), 998-1008.
87. Carroll, J.M.; Romero, M.R.; Watt, F.M. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell, 1995, 83(6), 957-968.
88. Kuphal, S.; Bauer, R.; Bosserhoff, A.K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev., 2005, 24(2), 195-222.
89. Semini, G.; Hildmann, A.; Reissig, H.U.; Reutter, W.; Danker, K. The novel synthetic ether lipid inositol-C2-PAF inhibits phosphorylation of the tyrosine kinases Src and FAK independent of integrin activation in transformed skin cells. Biochem. Pharmacol., 2011, 81(8), 985-995.
90. Chen, B.H.; Tzen, J.T.; Bresnick, A.R.; Chen, H.C. Roles of Rho-associated kinase and myosin light chain kinase in morphological and migratory defects of focal adhesion kinase-null cells. J. Biol. Chem., 2002, 277(37), 33857-33863.
91. Danker, K.; Gabriel, B.; Heidrich, C.; Reutter, W. Focal adhesion kinase pp125FAK and the beta 1 integrin subunit are constitutively complexed in HaCaT cells. Exp. Cell Res., 1998, 239(2), 326-331.
92. Mitra, S.K.; Hanson, D.A.; Schlaepfer, D.D. Focal adhesion kinase: In command and control of cell motility. Nat. Rev. Mol. Cell Biol., 2005, 6(1), 56-68.
93. Boelsma, E.; Verhoeven, M.C.; Ponec, M. Reconstruction of a human skin equivalent using a spontaneously transformed keratinocyte cell line(HaCaT). J. Investigat. Dermatol., 1999, 112(4), 489-498.
94. Clarke, P.A.; Te Poele, R.; Workman, P. Gene expression microarray technologies in the development of new therapeutic agents. Eur. J. Cancer, 2004, 40(17), 2560-2591.
95. Carrasco, M.P.; Jimenez-Lopez, J.M.; Rios-Marco, P.; Segovia, J.L.; Marco, C. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues. Br. J. Pharmacology, 2010, 160(2), 355-366.
96. Zhang, W.; Liu, W.; Poradosu, E.; Ratain, M.J. Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Human Genom., 2008, 3(1), 53-70.
97. Semini, G.; Klein, A.; Danker, K. Impact of alkylphospholipids on the gene expression profile of HaCaT cells. Pharmacogenet. Genom., 2011.
98. Lange, Y.; Steck, T.L. Cholesterol homeostasis. Modulation by amphiphiles. J. Biol. Chem., 1994, 269(47), 29371-29374.
99. Lange, Y.; Ye, J.; Rigney, M.; Steck, T.L. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J. Lipid Res., 1999, 40(12), 2264-2270.
100. Bryant, P.; Ploegh, H. Class II MHC peptide loading by the professionals. Curr. Opin. Immunol., 2004, 16(1), 96-102.
101. Kim, B.S.; Miyagawa, F.; Cho, Y.H.; Bennett, C.L.; Clausen, B.E.; Katz, S.I. Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis. J. Investigat. Dermatol., 2009, 129(12), 2805-2817.
102. Nickoloff, B.J.; Turka, L.A. Immunological functions of non-professional antigen-presenting cells: New insights from studies of T-cell interactions with keratinocytes. Immunol. Today, 1994, 15(10), 464-469.
103. Gottlieb, A.B.; Lifshitz, B.; Fu, S.M.; Staiano-Coico, L.; Wang, C.Y.; Carter, D.M. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. Exp. Med., 1986, 164(4), 1013-1028.
104. Friedrich, M.; Holzmann, R.; Sterry, W.; Wolk, K.; Truppel, A.; Piazena, H.; Schonbein, C.; Sabat, R.; Asadullah, K. Ultraviolet B radiation-mediated inhibition of interferon-gamma-induced keratinocyte activation is independent of interleukin-10 and other soluble mediators but associated with enhanced intracellular suppressors of cytokine-signaling expression. J. Investigat. Dermatol., 2003, 121(4), 845-852.
105. Gonzalez-Gay, M.A.; Nabozny, G.H.; Bull, M.J.; Zanelli, E.; Douhan, J., 3rd; Griffiths, M.M.; Glimcher, L.H.; Luthra, H.S.; David, C.S. Protective role of major histocompatibility complex class II Ebd transgene on collagen-induced arthritis. J. Exp. Med., 1994, 180(4), 1559-1564.
106. Krueger, J.G.; Krane, J.F.; Carter, D.M.; Gottlieb, A.B. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J. Investigat. Dermatol., 1990, 94(6 Suppl), 135S-140S.
107. Takagi, A.; Nishiyama, C.; Kanada, S.; Niwa, Y.; Fukuyama, K.; Ikeda, S.; Okumura, K.; Ogawa, H. Prolonged MHC class II expression and CIITA transcription in human keratinocytes. Biochem. Biophys. Res. Commun., 2006, 347(2), 388-393.
108. Mollinedo, F.; Gajate, C.; Morales, A.I.; Del Canto-Janez, E.; Justies, N.; Collia, F.; Rivas, J.V.; Modolell, M.; Iglesias, A. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J. Pharmacol. Exp. Ther., 2009, 329(2), 439-449.
109. Baumer, W.; Wlaz, P.; Jennings, G.; Rundfeldt, C. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models. Eu. J. Pharmacol., 2010, 628(1-3), 226-232.
110. Hochhuth, C.; Berkovic, D.; Eibl, H.; Unger, C.; Doenecke, D. Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells. J. Cancer Res. Clin. Oncol., 1990, 116(5), 459-466.
111. Roos, G.; Berdel, W.E. Sensitivity of human hematopoietic cell lines to an alkyl-lysophospholipid-derivative. Leuk. Res., 1986, 10(2), 195-202.
112. Wieder, T.; Haase, A.; Geilen, C.C.; Orfanos, C.E. The effect of two synthetic phospholipids on cell proliferation and phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. Lipids, 1995, 30(5), 389-393.
113. Edmondson, S.R.; Thumiger, S.P.; Kaur, P.; Loh, B.; Koelmeyer, R.; Li, A.; Silha, J.V.; Murphy, L.J.; Wraight, C.J.; Werther, G.A. Insulin-like growth factor binding protein-3(IGFBP-3) localizes to and modulates proliferative epidermal keratinocytes in vivo. The Br. J. Dermatol., 2005, 152(2), 225-230.
114. Hager, G.; Formanek, M.; Gedlicka, C.; Thurnher, D.; Knerer, B.; Kornfehl, J. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Oto-Laryngologica, 2001, 121(1), 103-109.
115. Hauser, P.; Ma, L.; Agrawal, D.; Haura, E.; Cress, W.D.; Pledger, W.J. Efficient down-regulation of cyclin A-associated activity and expression in suspended primary keratinocytes requires p21(Cip1). Mol. Cancer Res., 2004, 2(2), 96-104.
116. Massoner, P.; Colleselli, D.; Matscheski, A.; Pircher, H.; Geley, S.; Jansen Durr, P.; Klocker, H. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr. Related Cancer, 2009, 16(3), 795-808.